Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors

International Journal of Oncology

Volumn 30, Issue 1, 2007, Pages 123-128

  Söling, Ariane ^a   Plugge, Eva Maria ^a   Schmitz, Marc ^b   Weigle, Bernd ^b,c   Jacob, Roland ^a   Illert, Jörg ^a   Holzhausen, Hans Jürgen ^a   Rainov, Nikolai G ^a,d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Eucodis GmbH   (Austria)

^d KLINIKUM AUGSBURG   (Germany)

Author keywords

Autoantibodies; Glioma; Immunoblot; Meningioma; Survivin

Indexed keywords

AUTOANTIBODY; BIRC5 PROTEIN, HUMAN; IMMUNOGLOBULIN G; MICROTUBULE ASSOCIATED PROTEIN; RECOMBINANT PROTEIN; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD; BRAIN TUMOR; CANCER STAGING; GENETICS; GLIOMA; HUMAN; IMMUNOLOGY; MENINGIOMA; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE;

ADULT; AGED; APOPTOSIS; AUTOANTIBODIES; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOGLOBULIN G; MENINGIOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RECOMBINANT PROTEINS; REFERENCE VALUES;

EID: 39049179383     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.1.123     Document Type: Article

References (53)

1. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT and Koepsell TD: Epidemiology of intracranial meningioma. Cancer 72: 639-648, 1993.
2. Whittle IR, Smith C, Navoo P and Collie D: Meningiomas. Lancet 363: 1535-1543, 2004.
3. Perry A, Gutmann DH and Reifenberger G: Molecular pathogenesis of meningiomas. J Neurooncol 70: 183-202, 2004.
4. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG and Martuza RL: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62: 18-24, 1985.
5. Ohgaki H and Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489, 2005.
6. Cavenee WK, Weller M, Furnari FB, et al: Diffusely infiltrating astrocytomas. In: Tumours of the Nervous System. Kleihues P and Cavenee WK (eds). IARC Press, Lyon, pp10-54, 2000.
7. Von Deimling A, Louis DN and Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995.
8. Wen PY and Kesari S: Malignant gliomas. Curr Neurol Neurosci Rep 4: 218-227, 2004.
9. Mitchell P, Ellison DW and Mendelow AD: Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 4: 413-422, 2005.
10. Burton EC and Prados MD: Malignant gliomas. Curr Treat Options Oncol 1: 459-468, 2000.
11. Whittle IR: Surgery for gliomas. Curr Opin Neurol 15: 663-669, 2002.
12. Li F: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92: 212-216, 2005.
13. Caldas H, Honsey LE and Altura RA: Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol Cancer 4: 11-19, 2005.
14. Zaffaroni N, Pennati M and Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360-372, 2005.
15. Velculescu VE, Madden SL, Zhang L, et al: Analysis of human transcriptomes. Nat Genet 23: 387-388, 1999.
16. Shinohara ET, Gonzalez A, Massion PP, et al: Nuclear survivin predicts recurrence and poor survival in patients with resected non-small cell lung carcinoma. Cancer 103: 1685-1692, 2005.
17. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV and De Kok JB: Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50: 1986-1993, 2004.
18. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998.
19. Das A, Tan WL and Smith DR: Expression of the inhibitor of apoptosis protein survivin in benign meningiomas. Cancer Lett 193: 217-223, 2003.
20. Lusis EA, Chicoine MR and Perry A: High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol 73: 219-223, 2005.
21. Sasaki T, Lopes MB, Hankins GR and Helm GA: Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol (Berl) 104: 105-109, 2002. (Pubitemid 36075365)
22. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20: 1063-1068, 2002.
23. Das A, Tan WL, Teo J and Smith DR: Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 128: 302-306, 2002.
24. Kajiwara Y, Yamasaki F, Hama S, et al: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077-1083, 2003.
25. Yamada Y, Kuroiwa T, Nakagawa T, et al: Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99: 738-745, 2003.
26. Preusser M, Gelpi E, Matej R, et al: No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol (Berl) 109: 534-538, 2005.
27. Uematsu M, Ohsawa I, Aokage T, et al: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 72: 231-238, 2005.
28. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS and Guan XY: Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 94: 108-114, 2006.
29. Soussi T: P53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
30. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15: 3363-3367, 1997.
31. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK and Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136-143, 2003.
32. Rohayem J, Diestelkoetter P, Weigle B, et al: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60: 1815-1817, 2000.
33. Chang JT, Wong FH, Liao CT, Chen IH, Wang HM and Cheng AJ: Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 50: 1261-1264, 2004.
34. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC and thor Straten P: Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61: 5964-5968, 2001.
35. + T cells in colorectal cancer patients. Cancer Res 63: 4507-4515, 2003.
36. Idenoue S, Hirohashi Y, Torigoe T, et al: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11: 1474-1482, 2005.
37. Reymond D, Karmali MA, Clarke I, Winkler M and Petric M: Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1. J Clin Microbiol 35: 609-613, 1997.
38. Gekeler F, Eichenlaub S, Mendoza EG, Sotelo J, Hoelscher M and Loscher T: Sensitivity and specificity of ELISA and immunoblot for diagnosing neurocysticercosis. Eur J Clin Microbiol Infect Dis 21: 227-229, 2002.
39. Koziol JA, Zhang JY, Casiano CA, et al: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9: 5120-5126, 2003.
40. Yagihashi A, Asanuma K, Kobayashi D, et al: Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer 48: 217-221, 2005.
41. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60: 4845-4849, 2000.
42. Himoto T, Kuriyama S, Zhang JY, et al: Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 27: 1079-1085, 2005.
43. Kitamura H, Torigoe T, Honma I, et al: Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy. Urology 67: 955-959, 2006.
44. Yagihashi A, Ohmura T, Asanuma K, et al: Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 362: 125-130, 2005. (Pubitemid 41597098)
45. Katoh M, Wilmotte R, Belkouch MC, De Tribolet N, Pizzolato G and Dietrich PY: Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 64: 71-76, 2003.
46. Zhen HN, Zhang X, Hu PZ, et al: Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104: 2775-2783, 2005.
47. Comtesse N, Heckel D, Racz A, Brass N, Glass B and Meese E: Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping. Clin Cancer Res 5: 3560-3568, 1999.
48. Comtesse N, Zippel A, Walle S, et al: Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci USA 102: 9601-9606, 2005.
49. Schmits R, Cochlovius B, Treitz G, et al: Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int J Cancer 98: 73-77, 2002.
50. Soling A, Sackewitz M, Volkmar M, Schaarschmidt D, Jacob R, Holzhausen HJ and Rainov NG: Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res 11: 249-258, 2005.
51. Tan EM and Shi FD: Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 134: 169-177, 2003.
52. Kempuraj D, Devi RS, Madhappan B, et al: T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol 17: 57-64, 2004.
53. Rainov NG, Dobberstein KU, Fittkau M, Bahn H, Holzhausen HJ, Gantchev L and Burkert W: Absence of p53 autoantibodies in sera from glioma patients. Clin Cancer Res 1: 775-781, 1995.